Cargando…

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors

Detalles Bibliográficos
Autores principales:	Choi, Yun Jung, Park, Gun Min, Rho, Jin Kyung, Kim, Sun Ye, So, Gwang Sup, Kim, Hyeong Ryul, Choi, Chang-Min, Lee, Jae Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417663/ https://www.ncbi.nlm.nih.gov/pubmed/30870512 http://dx.doi.org/10.1371/journal.pone.0213984

Ejemplares similares

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Jung, Sangyong, et al.
Publicado: (2021)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR ‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial
por: Kim, Jiwon, et al.
Publicado: (2023)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Hempel, Cornelius, et al.
Publicado: (2017)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2016)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors
por: Ray, Paramita, et al.
Publicado: (2016)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Park, Ji Hyun, et al.
Publicado: (2016)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
por: Wang, Aoli, et al.
Publicado: (2016)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
por: Hong, Sook-hee, et al.
Publicado: (2022)

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
por: Lim, Sun Min, et al.
Publicado: (2016)

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Xia, Jinjing, et al.
Publicado: (2017)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n920t97vcu85k7s8hvfo3mgja3